% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Patil:178429,
      author       = {S. Patil$^*$ and B. Tawk$^*$ and M. Grosser and F.
                      Lohaus$^*$ and V. Gudziol and M. Kemper and A. Nowak and D.
                      Haim and I. Tinhofer$^*$ and V. Budach$^*$ and M.
                      Guberina$^*$ and M. Stuschke$^*$ and P. Balermpas$^*$ and C.
                      Rödel$^*$ and H. Schäfer$^*$ and A.-L. Grosu$^*$ and A.
                      Abdollahi$^*$ and J. Debus$^*$ and U. Ganswindt$^*$ and C.
                      Belka$^*$ and S. Pigorsch$^*$ and S. E. Combs$^*$ and S.
                      Boeke$^*$ and D. Zips$^*$ and G. B. Baretton$^*$ and M.
                      Baumann$^*$ and M. Krause$^*$ and S. Löck$^*$ and A.
                      Linge$^*$},
      collaboration = {DKTK-ROG},
      title        = {{A}nalyses of molecular subtypes and their association to
                      mechanisms of radioresistance in patients with
                      {HPV}-negative {HNSCC} treated bypostoperative
                      radiochemotherapy.},
      journal      = {Radiotherapy and oncology},
      volume       = {167},
      issn         = {0167-8140},
      address      = {Amsterdam [u.a.]},
      publisher    = {Elsevier Science},
      reportid     = {DKFZ-2022-00056},
      pages        = {300-307},
      year         = {2022},
      note         = {Volume 167, February 2022, Pages 300-307},
      abstract     = {To assess the relation of the previously reported
                      classification of molecular subtypes to the outcome of
                      patients with HNSCC treated with postoperative
                      radio(chemo)therapy (PORT-C), and to assess the association
                      of these subtypes with gene expressions reflecting known
                      mechanisms of radioresistance.Gene expression analyses were
                      performed using the GeneChip Human Transcriptome Array 2.0
                      on a multicentre retrospective patient cohort (N=128) of the
                      German Cancer Consortium Radiation Oncology Group (DKTK-ROG)
                      with locally advanced HNSCC treated with PORT-C. Tumours
                      were assigned to four molecular subtypes, and correlation
                      analyses between subtypes and clinical risk factors were
                      performed. In addition, the classifications of eight genes
                      or gene signatures related to mechanisms of radioresistance,
                      which have previously shown an association with outcome of
                      patients with HNSCC, were compared between the molecular
                      subtypes. The endpoints loco-regional control (LRC) and
                      overall survival (OS) were evaluated by log-rank tests and
                      Cox regression.Tumours were classified into the four
                      subtypes basal $(19.5\%),$ mesenchymal $(18.8\%),$ atypical
                      $(15.6\%)$ and classical $(14.1\%).$ The remaining tumours
                      could not be classified $(32.0\%).$ Tumours of the
                      mesenchymal subtype showed a lower LRC compared to the other
                      subtypes (p=0.012). These tumours were associated with
                      increased epithelial-mesenchymal transition (EMT) and
                      overexpression of a gene signature enriched in DNA repair
                      genes. The majority of the eight considered gene classifiers
                      were significantly associated to LRC or OS in the whole
                      cohort.Molecular subtypes, previously identified on HNSCC
                      patients treated with primary radio(chemo)therapy or
                      surgery, were related to LRC for patients treated with
                      PORT-C, where mesenchymal tumour presented with worse
                      prognosis. After prospective validation, subtype-based
                      patient stratification, potentially in combination with
                      other molecular classifiers, may be considered in future
                      interventional studies in the context of personalised
                      radiotherapy and may guide the development of combined
                      treatment approaches.},
      keywords     = {cancer stem cells (Other) / gene signatures (Other) / head
                      and neck squamous cell carcinoma (Other) / hypoxia (Other) /
                      postoperative radiotherapy (Other) / primary radiotherapy
                      (Other)},
      cin          = {DD01 / E210 / HD01 / BE01 / ED01 / FM01 / FR01 / E050 /
                      E220},
      ddc          = {610},
      cid          = {I:(DE-He78)DD01-20160331 / I:(DE-He78)E210-20160331 /
                      I:(DE-He78)HD01-20160331 / I:(DE-He78)BE01-20160331 /
                      I:(DE-He78)ED01-20160331 / I:(DE-He78)FM01-20160331 /
                      I:(DE-He78)FR01-20160331 / I:(DE-He78)E050-20160331 /
                      I:(DE-He78)E220-20160331},
      pnm          = {315 - Bildgebung und Radioonkologie (POF4-315)},
      pid          = {G:(DE-HGF)POF4-315},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:34999136},
      doi          = {10.1016/j.radonc.2021.12.049},
      url          = {https://inrepo02.dkfz.de/record/178429},
}